Fortune recently released its annual "Fortune 500" rankings of businesses—and plenty of biopharma firms made the cut.
According to Fortune, the companies on the list are "ranked by total revenues for their respective fiscal years. Included in the survey are companies that are incorporated in the U.S. and operate in the U.S. and file financial statements with a government agency."
The list is highly interactive. You can filter the rankings by industry, by market value, by profits and profit change, and much more. Here are some highlights from this year's rankings.
The 17 pharmas that made the list
All told, 17 biopharma companies made the cut (that's excluding other healthcare companies like pharmacy benefits managers), ranging from #37 on the list (Johnson & Johnson) to #941 (Alexion Pharma—yes, the list is decidedly more than just 500 companies).
By overall ranking, here are the companies:
37) Johnson & Johnson
118) Gilead Sciences
151) Eli Lilly
195) Bristol-Myers Squibb
664) Forest Labs
941) Alexion Pharma
Notably, almost every single one of these companies was profitable in 2014—with one exception: New York's NBTY, a manufacturer of vitamins and nutritional supplements that was formerly known as Nature's Bounty.
One company cracked the top 10 of the entire list in terms of overall profits: Johnson & Johnson, which "posted the second-largest profit growth in 2014 after J.P. Morgan," according to Fortune. J&J saw 18% profit boosts thanks to strong pharma sales in hepatitis C, diabetes, and prostate cancer despite a tougher landscape for its formidable medical devices business.
Gilead, Merck, and Pfizer placed in the top 20 most profitable companies. Biogen was the only other biopharma to crack the top 100 most profitable on the list.
Other notables: Of the 17 biopharma companies on the list, 12 actually experienced job growth in the past year: Pfizer, Gilead, AbbVie, Lilly, Biogen, Celgene, Zoetis, Hospira, Forest Labs, NBTY, Regeneron, and Alexion.
Check out more details and play around with the full list here.